Pixclara FET-PET glioma tracer administered to first U.S. patients

Pixclara—the first FDA-approved FET-PET tracer for glioma—has been administered to its first U.S. patients. Now commercially available, it aids in evaluating suspected recurrence. Gliomas account for ~24,000 new cases annually, representing a significant unmet need.

• Pixclara (floretyrosine F 18) is the first FDA-approved FET-PET tracer for glioma, already standard of care overseas.
• IU Health and University Hospitals Cleveland Medical Center were among the first U.S. sites to administer the commercial dose.
• The agent addresses an unmet need: ~24,000 new glioma cases are diagnosed annually in the U.S.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.